Most medical device companies begin with an engineer's idea and then search for a clinical problem to fit it. RC Medical, a venture studio based in Lake Forest, California, works the other way around, according to its chief executive, David Ferrera.
"We go to the interventional suite first," Ferrera said. "The physicians there see the gaps every week. Our job is to listen, then build the company around what they're actually describing."
The distinction matters for the interventional radiology market, where devices are used in minimally invasive procedures guided by imaging. RC Medical funds, designs, develops and commercializes products in that field, but it does not take on contract work for outside clients. Instead, it partners directly with physician-entrepreneurs to identify new technology and new indications for devices, then forms a standalone company to carry each idea forward.
For physicians, the arrangement is presented as a partnership rather than a handoff. Ferrera said a physician who brings an idea to the studio stays involved from the first sketch through commercialization, while RC Medical supplies the engineering, the regulatory path and the business discipline needed to turn a clinical problem into something that can reach patients.
"A physician knows the problem better than anyone," he said. "What we bring is the engineering, the regulatory path, and the discipline to turn that problem into something that can actually reach patients. Neither side can do it alone."
When an idea clears the studio's early evaluation, RC Medical does not fold it into an existing product line. It creates a new company with its own team and its own focus. That approach has produced three separate companies out of the studio: Single Pass, Infinity Neuro and Sonorous NV. Each grew out of a specific problem a physician described in the interventional suite, and each operates as its own business rather than as a product line inside RC Medical.
"A big portfolio company can lose a good idea in the shuffle," Ferrera said. "A newco can't afford to."
The rationale rests on a detail Ferrera says traditional product development tends to miss. A catheter that works in a textbook case can still fail in the specific anatomy a physician encounters regularly, and that detail does not surface unless a device is built with the physician rather than for them. Catching it early, before a design is locked in and hard to change, is the studio model's central promise.
Ferrera brings close to three decades of device experience to the role, including co-founding Blockade Medical, which was acquired by Balt Extrusion in 2016, and serving as chief technology officer of Balt Global. He is also the author of "Innovation in Translation: How Big Ideas Really Happen," published by Forbes Books in 2021.
The implications extend beyond one studio. Physician-led innovation has become a recognized pathway for bringing clinical insight into device development, and RC Medical's structure offers a template in which clinicians retain a stake in the outcome. Ferrera is candid that the model is not universal. Some ideas, he said, are better as a feature of an existing product than as a new company, and part of the first conversation with a physician is being honest about which one applies. For those that do become companies, the physician's involvement typically continues through development and toward the market, keeping the clinical need in view at every stage rather than only at the start.
